drugset / Trial / NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last participant transitions with quarterly study evaluations.
Timeline
- Start
- 2009-07-21
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navitoclax | Small molecule | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |